Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open label, randomized, single center trial in healthy young women, to evaluate the effects of a monophasic combined oral contraceptive (COC) containing 2.5 mg NOMAC [nomegestrol] and 1.5 mg E2 [ethinyl estradiol] on bone mineral density (BMD) compared to a monophasic COC containing 0.150 mg levonorgestrel and 0.030 mg ethinyl estradiol.

Trial Profile

An open label, randomized, single center trial in healthy young women, to evaluate the effects of a monophasic combined oral contraceptive (COC) containing 2.5 mg NOMAC [nomegestrol] and 1.5 mg E2 [ethinyl estradiol] on bone mineral density (BMD) compared to a monophasic COC containing 0.150 mg levonorgestrel and 0.030 mg ethinyl estradiol.

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Jun 2014

At a glance

  • Drugs Estradiol/nomegestrol (Primary) ; Ethinylestradiol/levonorgestrel
  • Indications Pregnancy
  • Focus Pharmacodynamics
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 16 Sep 2009 Actual end date (Jun 2009) added as reported by ClinicalTrials.gov.
    • 16 Sep 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 24 Jan 2008 The expected completion date for this trial is now 1 Aug 2009.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top